The Food and Drug Administration approved a new version of kaléo's epinephrine auto-injector, Auvi-Q, specifically designed for children.
Here are three things to know.
- The Auvi-Q 0.1 milligram auto-injector is intended to treat infants and young children who weigh 16.5 to 33 pounds and are at risk for serious allergic reactions.
- The device contains a shorter needle and lower epinephrine dose than other Auvi-Q auto-injectors already on the market.
- Kaléo expects Auvi-Q 0.1 milligram to be available for patients by mid-2018.